» Articles » PMID: 35408729

Two Green Micellar HPLC and Mathematically Assisted UV Spectroscopic Methods for the Simultaneous Determination of Molnupiravir and Favipiravir As a Novel Combined COVID-19 Antiviral Regimen

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2022 Apr 12
PMID 35408729
Authors
Affiliations
Soon will be listed here.
Abstract

Following the spread of the COVID-19 pandemic crisis, a race was initiated to find a successful regimen for postinfections. Among those trials, a recent study declared the efficacy of an antiviral combination of favipiravir (FAV) and molnupiravir (MLP). The combined regimen helped in a successful 60% eradication of the SARS-CoV-2 virus from the lungs of studied hamster models. Moreover, it prevented viral transmission to cohosted sentinels. Because both medications are orally bioavailable, the coformulation of FAV and MLP can be predicted. The developed study is aimed at developing new green and simple methods for the simultaneous determination of FAV and MLP and then at their application in the study of their dissolution behavior if coformulated together. A green micellar HPLC method was validated using an RP-C18 core-shell column (5 μm, 150 × 4.6 mm) and an isocratic mixed micellar mobile phase composed of 0.1 M SDS, 0.01 M Brij-35, and 0.02 M monobasic potassium phosphate mixture and adjusted to pH 3.1 at 1.0 mL min flow rate. The analytes were detected at 230 nm. The run time was less than five minutes under the optimized chromatographic conditions. Four other multivariate chemometric model methods were developed and validated, namely, classical least square (CLS), principal component regression (PCR), partial least squares (PLS-1), and genetic algorithm-partial least squares (GA-PLS-1). The developed models succeeded in resolving the great similarity and overlapping in the FAV and MLP UV spectra unlike the traditional univariate methods. All methods were organic solvent-free, did not require extraction or derivatization steps, and were applied for the construction of the simultaneous dissolution profile for FAV tablets and MLP capsules. The methods revealed that the amount of the simultaneously released cited drugs increases up until reaching a plateau after 15 and 20 min for FAV and MLP, respectively. The greenness was assessed on GAPI and found to be in harmony with green analytical chemistry concepts.

Citing Articles

QbD-steered HPTLC approach for concurrent estimation of six co-administered COVID-19 and cardiovascular drugs in different matrices: greenness appraisal.

Mohamed A, Sayed R, Shalaby A, Ibrahim H Sci Rep. 2025; 15(1):6252.

PMID: 39979403 PMC: 11842590. DOI: 10.1038/s41598-024-83692-x.


Garlic peel-based carbon quantum dots as a sustainable alternative for the sensitive and green spectrofluorometric quantification of molnupiravir in pharmaceutical capsules.

Saber Y, Hamed M, Emara S, Mansour F, Locatelli M, Ibrahim N Heliyon. 2024; 10(23):e40661.

PMID: 39698097 PMC: 11652926. DOI: 10.1016/j.heliyon.2024.e40661.


A comparative study of electropolymerization and photopolymerization for the determination of molnupiravir and their application in an electrochemical sensor via computationally designed molecularly imprinted polymers.

Cetinkaya A, Unal M, Nazir H, Corman M, Uzun L, Ozkan S Mikrochim Acta. 2024; 191(5):270.

PMID: 38630200 PMC: 11024036. DOI: 10.1007/s00604-024-06353-w.


Surface engineering of carbon microspheres with nanoceria wrapped on MWCNTs: a dual electrocatalyst for simultaneous monitoring of molnupiravir and paracetamol.

Alqahtani Y, Mahmoud A, El-Wekil M, Ibrahim H RSC Adv. 2024; 14(8):5406-5416.

PMID: 38348296 PMC: 10860542. DOI: 10.1039/d3ra08098f.


A solvent-free HPLC method for the simultaneous determination of Favipiravir and its hydrolytic degradation product.

Sharaf Y, Abd El-Fattah M, El-Sayed H, Hassan S Sci Rep. 2023; 13(1):18512.

PMID: 37898682 PMC: 10613211. DOI: 10.1038/s41598-023-45618-x.


References
1.
Gowen B, Sefing E, Westover J, Smee D, Hagloch J, Furuta Y . Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever. Antiviral Res. 2015; 121:132-7. PMC: 4536130. DOI: 10.1016/j.antiviral.2015.07.003. View

2.
Megahed S, Habib A, Hammad S, Kamal A . Experimental design approach for development of spectrofluorimetric method for determination of favipiravir; a potential therapeutic agent against COVID-19 virus: Application to spiked human plasma. Spectrochim Acta A Mol Biomol Spectrosc. 2020; 249:119241. PMC: 7834856. DOI: 10.1016/j.saa.2020.119241. View

3.
Marzouk H, Rezk M, Gouda A, Abdel-Megied A . A novel stability-indicating HPLC-DAD method for determination of favipiravir, a potential antiviral drug for COVID-19 treatment; application to degradation kinetic studies and in-vitro dissolution profiling. Microchem J. 2021; 172:106917. PMC: 8518200. DOI: 10.1016/j.microc.2021.106917. View

4.
Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J . Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering (Beijing). 2020; 6(10):1192-1198. PMC: 7185795. DOI: 10.1016/j.eng.2020.03.007. View

5.
Abdelnabi R, Foo C, Kaptein S, Zhang X, Do T, Langendries L . The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model. EBioMedicine. 2021; 72:103595. PMC: 8461366. DOI: 10.1016/j.ebiom.2021.103595. View